



(51) International Patent Classification:

A61K 39/155 (2006.01) C07K 14/135 (2006.01)
C07K 14/115 (2006.01)

(21) International Application Number:

PCT/EP2010/059006

(22) International Filing Date:

24 June 2010 (24.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/219,958 24 June 2009 (24.06.2009) US

(71) Applicants (for all designated States except US):

BIOMEDICAL CORPORATION OF QUEBEC [CA/CA]; 525 Cartier Boulevard West, Laval, Québec H7V 3S8 (CA). **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLAIS, Normand** [CA/CA]; GlaxoSmithKline Biologicals Laval, 525 Cartier Boulevard West, Laval, Québec H7V 3S8 (CA). **RHEAULT, Patrick** [CA/CA]; GlaxoSmithKline Biologicals Laval, 525 Cartier Boulevard West, Laval, Québec H7V 3S8 (CA). **VAN-SCHERPENZEEL-THIM, Virginie** [BE/BE]; GlaxoSmithKline Biologicals

s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **VAS-SILEV, Ventzislav** [BG/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE).


(74) Agents: **DALTON, Marcus Jonathan William** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: VACCINE



(57) Abstract: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapneumovirus (hMPV), parainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided.



Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
10 March 2011